menu
    • menu
    [{"orgOrder":0,"company":"Chimeron Bio","sponsor":"Mason University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Self-Amplifying Rna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeron Bio \/ Mason University","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron Bio \/ Mason University"},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeron Bio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron Bio \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Chimeron Bio

    Menu

    Chimeron Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chimeron Bio

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Chimeron Bio

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Chimeron Bio Enters Into an Agreement With the NIAID, a Federal Agency, for Pre-clinical Assessment of Its Sel...

                            Details : Under the current agreement, Chimeron Bio will utilize the pre-clinical services program offered by the NIAID. The Company’s lead candidate, CB-106, delivers the Spike gene as a self-amplifying mRNA.

                            Product Name : CB-106

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 21, 2022

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chimeron Bio

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Chimeron Bio

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Self-Amplifying Rna Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Mason University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Chimeron Bio and George Mason University Partner to Develop a Coronavirus Vaccine using ChaESARTM Technology

                            Details : The vaccine development will be based on Chimeron Bio’s ChaESARTM self-amplifying RNA technology and will integrate Mason’s complimenting expertise and Biomedical Research Laboratory (BRL).

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : Self-Amplifying Rna Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Mason University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth